Monopar Therapeutics (MNPR) CCSO granted 48,728 stock options in new award

Rhea-AI Filing Summary

Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.

Monopar Therapeutics granted Chief Clinical Science Officer Susan Rodriguez stock options covering 48,728 shares on March 2, 2026. The options were reported at a price of $0.0000 per share and are held directly.

According to the vesting terms, 6/48ths of the options vest on September 2, 2026, with the remaining 1/48th vesting each month thereafter. After this grant, Rodriguez was reported as holding 48,728 stock options in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rodriguez Susan

Role CCSO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	48,728	$0.00	--

Holdings After Transaction: Stock Options — 48,728 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodriguez Susan

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CCSO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$53.47	03/02/2026		A		48,728		(1)	03/02/2036	Common Stock	48,728	$0	48,728	D

Explanation of Responses:

1. Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter.

	/s/ Quan Vu, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monopar Therapeutics (MNPR) report for Susan Rodriguez?

Monopar Therapeutics granted Susan Rodriguez stock options for 48,728 shares on March 2, 2026. These options are held directly and represent a grant or award acquisition rather than an open-market purchase or sale of existing shares.

What is the vesting schedule for Susan Rodriguez’s 48,728 Monopar (MNPR) stock options?

The 48,728 stock options vest 6/48ths on September 2, 2026, then 1/48th each month afterward. This structure delays initial vesting and then spreads remaining vesting evenly over subsequent months, aligning compensation with ongoing service.

What role does Susan Rodriguez hold at Monopar Therapeutics (MNPR) in this Form 4?

Susan Rodriguez is identified as an officer of Monopar Therapeutics, serving as Chief Clinical Science Officer (CCSO). The reported stock option grant reflects part of her compensation in that executive capacity rather than a discretionary market trade.

How many Monopar Therapeutics (MNPR) stock options does Susan Rodriguez hold after this grant?

Following the reported transaction, Susan Rodriguez holds 48,728 Monopar Therapeutics stock options. This total matches the number of options granted in the transaction, indicating these are newly awarded derivative securities rather than additional accumulations.

Did Susan Rodriguez buy or sell Monopar Therapeutics (MNPR) common shares in this transaction?

No common share buy or sell occurred. The Form 4 shows a grant of 48,728 stock options at a reported price of $0.0000 per share, categorized as a grant, award, or other acquisition of derivative securities, not an open-market trade.